Combination cancer therapy
CL202601369A1Pending Publication Date: 2026-08-21BOEHRINGER INGELHEIM INT GMBH
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- CL202601369
- Authority / Receiving Office
- CL · CL
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-12-18
- Filing Date
- 2026-04-28
- Publication Date
- 2026-08-21
Abstract
The present invention relates to the combination of the HER2 tyrosine kinase inhibitor, zongertinib, with an anti-HER2 antibody and / or an anti-HER2 antibody-drug conjugate. This combination may further comprise an additional anticancer drug. The combination of the invention is useful for the treatment and / or prevention of oncological and / or hyperproliferative diseases, such as cancer. Therefore, the invention provides compounds for uses, methods of prevention and / or treatment, pharmaceutical compositions, and kits related to the combination.
Need to check novelty before this filing date? Find Prior Art